Layer-by-Layer (LbL) self-assembly of nanocarriers has garnered the interest of researchers for a wide variety of biomedical applications. In this study, we demonstrated the preparation of poly(lactide-coglycolide) (PLGA)-(poly-L-ornithine (PLO)/fucoidan) 4 core-shell nanoparticles (LbL NPs) by a LbL-based self-assembly process, which possessed a mean size of 170 nm. In LbL NPs, a drug carrying PLGA nanocore is coated with alternating PLO and sulfated polysaccharide fucoidan composite films as a shell on the surface. The anti-tumor drug doxorubicin (DOX) loaded into the PLGA core, resulted in better encapsulation efficiency and its in vitro release from LbL NPs demonstrates that this core-shell strategy takes an advantage of its ability to hold the drug cargo and exhibit controlled release. Further, in vitro cell uptake studies by confocal laser scanning microscopy (CLSM) examination in breast tumor cells (MCF-7 cell line) have confirmed that the nanocarriers are successfully internalized and outlined their presence in the cytoplasm after 4 h of incubation. These intracellularly delivered DOX-loaded LbL NPs exhibited significant anti-tumor activity against breast tumor cells. This innovative chemotherapeutic design taking above advantages of successful internalization along with controlled release property signifies as a promising interventional therapeutic delivery system.
Introduction
Layer-by-layer (LbL) self-assembly is one of the deposition techniques uses the basement to alternately adsorb two or more polyvalent materials in the polymer solution through electrostatic interactions. 1 Kotov et al. had made a signicant contribution towards this process, by demonstrating a versatile method of LbL self-assembly of polycations and semiconductor nanoparticles (NPs) into stable ultrathin lms. 2 Decher also made an important breakthrough in this technology using ionized polyelectrolytes i.e., poly(styrene sulfonate) and poly(allylamine hydrochloride) deposited as multi-layers through electrostatic attraction on the solid base. 3 The preparation method is so simple as it depends on precise stoichiometry to prepare multilayer coatings by a complex chemical reaction, and convenient, because it does not require any sophisticated equipment. Functional thin lms could be generated by the LbL self-assembly method aer adsorption on solid surfaces. Meanwhile, assembling an LbL system may exploit hydrophobic interaction, hydrogen binding and van der Waals forces, which inuence the stability, morphology and thickness of the lms. 4 These lms have been approved for various applications including the biological sensing, drug and gene delivery, regenerative medicine, tissue engineering and bionic medicine. Because of the mild reaction conditions and high drug-loading capability, LbL drug carriers have been applied as a new drug delivery system in nanomedicine research.
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This self-assembly technology combines different polyelectrolyte materials to construct an ultrathin carrier with multilayer membrane structure. According to the source of the materials, the polyelectrolyte materials are classied into different categories, including synthetic and natural type polyelectrolytes. 8 Herewith, we designed the shell LbL assembly using two functional polymers i.e., poly-L-ornithine (PLO) and fucoidan. PLO (Fig. 1a) is a biocompatible and low immunogenic polyelectrolyte, 9 within a primary amine side chain and charged when exposed to physiological environment, similar to poly-L-arginine, poly-L-lysine. 10 PLO possesses a wide variety of biological activities, such as enhancing the proliferation, migration and neuronal differentiation/regeneration responses of neural stem/progenitor cells, and also enhances the nasal absorption of hydrophilic macromolecular drugs.
11-14 PLO also holds good mechanical properties and enhances drug permeability. 15, 16 Fucoidan (Fig. 1b) is another component of self-assembly, which contains L-fucose and sulfate groups.
17,18
This compound also possesses a variety of biological activities such as anti-coagulation, hypolipidemic, anti-tumor, anti-viral activity, and a property of strengthening the body's immune function. [19] [20] [21] Fucoidan induces the apoptosis in tumor cells 22 or affects the proliferation of tumor cells, 23 and could be used as potential anti-tumor drug to act against colon and breast cancers.
24,25
Doxorubicin (DOX) is an anthracycline-based broadspectrum anticancer drug, which is widely used against various malignancies such as liver, lung, breast, and ovarian cancers. However, higher doses or frequency of administration resulted in toxic side effects associated with heart and digestive tract. 26 To overcome this limitation, we designed a delivery system using polymers possessing anti-proliferative ability with the minimal amount of drug. Herewith, we demonstrated the encapsulation of anti-tumor drug DOX in a highly biocompatible and biodegradable PLGA nano-core for better performance using the emulsion solvent evaporation method. Subsequently, the shell deposited surrounding the nano-core comprises of polyelectrolytes, PLO as well as fucoidan, alternatively to prepare core-shell type PLGA-(PLO/fucoidan) n (Fig. 2a) . Initially, the morphology and physico-chemical properties are well characterized. Further, the DOX loading efficiency and its releasing prole are examined in LbL NPs (as shown in Fig. 2b) . Later, the in vitro anti-proliferative ability of drug-loaded coreshell LbL NPs is investigated using breast cancer cell lines (MCF-7) as the tumor model. We anticipate that this innovative material design could provide a new chance and alternative option for the tough choices of LbL membrane materials, and the pharmacological properties of these materials would be benecial for the effective treatment as interventional therapy in the future applications such as drug delivery system, surgical dressing, articial skin, mucous membrane, degradable lms, and others.
Materials and methods

Materials
Poly(lactide-co-glycolide) (PLGA) (D, L-lactide : glycolide ¼ 50 : 50) with an average molecular weight of 70-100 KDa and poly-L-ornithine (molecular weight 30-70 KDa) were purchased from Sigma-Aldrich. 
Preparation of PLGA NPs and DOX-PLGA NPs
PLGA NPs were prepared using O/W emulsion-solvent evaporation method as reported. 27 At rst, PLGA (40 mg) was solubilized in dichloromethane (DCM), which acts as an oil phase in the design, alternatively BSA aqueous solution (8 mL) as the water phase. BSA acted as the surfactant (or stabilizer) for the emulsion process which could help the forming of PLGA NPs. Later, the oil phase was added drop-wise to the water phase and subjected to the ultra-sonication (SCIENTZ, JY92-2D) for nanoemulsion preparation. Then, the mixed emulsion was poured into 200 mL of water and stirred for 3 h. Subsequently, the liquid organic phase was evaporated and the nanoparticles were washed repeatedly for 5 times by centrifuging at 10 000g, for 5 min.
Doxorubicin loaded PLGA NPs were prepared following similar procedure as described above. Initially, PLGA (60 mg) was dissolved in DCM (3 mL) with 0.6 mL of DOX solution (10 mg mL À1 in methanol and chloroform mixture (1 : 1)). This solution was subsequently added drop-wise to 12 mL BSA in water, which was then emulsied by an ultrasonicator for 20 s. This emulsion was immediately poured into 300 mL of water and stirred for 3 h. The resulting particle suspension was puried via centrifugation (10 000g, 5 min) ahead of LbL assembly, eventually.
Preparation of PLGA-(PLO/fucoidan) 4 NPs (LbL NPs)
The PLO and fucoidan polymers were self-assembled layer upon a layer alternatively at a polyelectrolyte concentration of 1 mg mL À1 . PLGA NPs/DOX-PLGA NPs (10 mg) as cores were added into 10 mL of polyelectrolyte solution subsequently one aer the other through static adsorption, resulting in polyelectrolyte multi-layer lms. The excess polyelectrolyte solution was washed-out using water. PLGA-(PLO/fucoidan) 4 NPs were prepared by repeating the process successively for multiple times. Herewith, we have repeated the layers for different times and the samples were named as PLGA-(PLO/fucoidan) 0.5 NPs, PLGA-(PLO/fucoidan) 1 NPs, PLGA-(PLO/fucoidan) 1.5 NPs, etc. Similarly, the DOX-PLGA NPs were also prepared following the above process to deposit multi-layered polymers. The whole processing steps of LbL NPs formation were illustrated in Fig. 3 .
Microstructure and phase analyzing behavior study
The extensive morphological study of freeze-dried PLGA NPs and PLGA-(PLO/fucoidan) 4 NPs was performed by transmission electron microscope (TEM, TEM 8400S, Shimadzu, Japan). Prepared nanoparticles (from PLGA cores to PLGA-(PLO/ fucoidan) 10 NPs), each successive bilayer nanoparticles were homogeneously dispersed in water for the dynamic light scattering (DLS) measurements and instantaneously zeta-potential values of subsequent LbL nanoparticles (from PLGA NPs to PLGA-(PLO/fucoidan) 5 NPs) aer each PLO or fucoidan layer was also observed.
In vitro drug loading and drug release study
The DOX loading efficiency of various nanoparticle formulations was tested by following the procedure below. Initially, 5 mg of NPs (DOX-PLGA NPs and DOX-PLGA-(PLO/fucoidan) 4 NPs) were loaded DOX in different drug dosage, 5 wt% (0.25 mg), 10 wt% (0.50 mg), 15 wt% (0.75 mg), respectively. At rst, they were dissolved in DCM and appropriate amount of the phosphate buffered saline (PBS (pH-7.4)) solution was added and mixed under stirring until DCM volatilize completely. The remaining mixture was ltered using 0.22 mm membrane, and diluted appropriately. The absorbance of the resulting solution was recorded eventually using UV-Vis spectrophotometer, compared with PBS as blank. The experiment was performed in triplicate.
In a typical in vitro drug release study, 1.0 mg of doxorubicin equivalent amount was set as a baseline, according to the actual drug loading efficiency of nanoparticles. For an instance, according to the optimum drug loading condition, DOX loaded PLGA NPs and PLGA-(PLO/fucoidan) 4 NPs and 1.0 mg of pure DOX were suspended separately in 30 mL of PBS, mounted in dialysis bags, maintained at 37 C and stirred at 60 RPM. Sampling was done by taking 3 mL of PBS from the dialysis bag at various time intervals (0.5, 1, 2, 3, 4, 6, 9, 12, 24, 36, 48, and 72 h) and the study continued by replacing the simulated uids at the respective time intervals. The cumulative release percentage was calculated by measuring the drug concentration in the solution phase periodically using UV-Vis spectrophotometer. Fig. 3 Schematic illustration of preparation steps of PLGA-(PLO/fucoidan) n nanoparticles by ultrasonic emulsification of LbL self-assembly. 4 NPs (which were prepared in the optimum drug loading condition) suspended in culture medium was added to substantiate the dose-dependent toxicity. Aer 24 h of incubation, the absorbance of cells was observed following the manufacturer's instructions of CCK-8 kit. In addition, timedependent cytotoxicity study was performed by adding 100 mL of 5 mg mL À1 drug loading PLGA NPs and PLGA-(PLO/fucoidan) 4 NPs suspension in the culture medium and incubated for 24, 48, and 72 h. Similarly, the results were recorded following the above procedure.
In vitro anti-tumor activity
CLSM imaging
Cell internalization of design nanoconstructs was traced using CLSM imaging. MCF-7 cells were seeded at a density of 5 Â 10 5 cells per well, placing glass cover slips on a confocal laser plate and allowed to adhere for 48 h. Later, the medium was removed and 3 mL of 5 mg mL À1 of DOX-PLGA-(PLO/fucoidan) 4 NPs (in the optimum drug loading condition) suspended in culture medium was added. Aer respective time intervals (0.5, 2, and 4 h) of incubation, the medium was removed and cells were washed with cold PBS and xed using paraformaldehyde for 15 min. Cells were then washed again with PBS, and then one drop of DAPI solution was added onto the glass cover slips in confocal laser plates. Confocal laser scanning uorescence imaging was performed with a Zeiss LSM710 confocal microscope (Carl Zeiss Microscopy GmbHm Jena, Germany) to capture images.
Results and discussion
The morphology of PLGA NPs and PLGA-(PLO/fucoidan) 4 NPs
From the TEM images shown in Fig. 4 , it is evident that the PLGA core nanoparticle was more or less spherical in shape (Fig. 4a) . Aer self-assembling of polyelectrolyte materials, the surface became a bit irregular, which conrmed the external shallow shell (Fig. 4b) . The particle size of various designed nanocarriers was obtained by the nano measurer soware analysis, where PLGA core size was recorded as 112 nm. Meanwhile, aer the self-assembly process, the particle size was increased to a range of 165-180 nm (Fig. 4b) , which is suitable for ease of cell internalization, Fig. 4c had shown that the dispersed LbL NPs resulted in the detached polyelectrolyte layers due to ultrasonic treatment subsequently for each coating. However, no signicant reduction in the size of the LbL NPs was eventually observed. Comparing with the report of Romero, 27 who used the emulsied volatile method to prepare PLGA nanoparticles and Ramasamy, 28 who elucidated the morphology of self-assembly nanoparticles, it was similar representing the external irregular polyelectrolyte coatings, however the undesirable aggregation was not perceived.
Size distribution of PLGA NPs and PLGA-(PLO/fucoidan) 4 NPs
The particle size distributions of the designed PLGA NPs and self-assembled bilayers (PLGA-(PLO/fucoidan) n ) on the surface are shown in Fig. 5 . The average particle size of PLGA cores was 110 nm, with the increasing layer number, particle size increased gradually. Aer assembling of 4 bilayers, particle size was 170 nm, which increased to 299 nm aer the assembly of 10 bilayers membrane. The data represents that the average size of each bilayer membrane was $19 nm, whereas the poly(styrenesulfonate)/polyvinylpyrrolidone lms prepared by Strydom group 29 resulted in 9 AE 1 nm bilayer membrane size. The larger size might have resulted because of hydration of NPs, 27 since the particles were dispersed in water medium during DLS recordings, and other assumption might be the variations in polyelectrolyte, which also result in size disparity. However, as a drug delivery carrier, the layer number of assembly could satisfy the specic requirements with respective to controlled drug delivery and anti-proliferative activity. These DLS recordings were in agreement with the TEM measurements.
Zeta (z)-potential measurements
Aer depositing the different polyelectrolyte alternatively to form a nano single-layer lm, the charge was ipped for each step, as shown in Fig. 6 . The average surface z-potential of PLGA NPs cores was À25 AE 1 mV, while of the positive potential was +30 AE 2 mV and the negative potential was À24 AE 2 mV, which represented that the polyelectrolyte membranes had good stability with consistency in this system and the results were in agreement with the reports published elsewhere.
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In vitro drug loading and drug release study
The results of drug loading and encapsulation efficiency were shown in Fig. 7 . The optimal drug loading conditions were optimized by altering the conditions such as increasing in drug amount (5 wt%, 10 wt%, 15 wt%), in both DOX-PLGA NPs and DOX-PLGA-(PLO/fucoidan) 4 NPs. The results showed that the drug loading amount increased with the increase of drug amount. However, the encapsulation efficiency decreased gradually. The DOX loading amount in PLGA NPs at various drug amounts was 3.9%, 6.8%, and 8.6% respectively, while in LbL NPs, it was 2.1%, 3.5%, and 4.8%. The encapsulation efficiency of DOX-PLGA NPs was 81.4%, 72.6%, 63.1%, DOX-PLGA-(PLO/fucoidan) 4 NPs was 42.5%, 36.6%, 33.7%, when the DOX was fed as the ratio of 5 wt%, 10 wt%, 15 wt% the NPs, respectively. PLGA NPs and LbL NPs with 10 wt% of DOX were used in further experiments. The optimized formulation 10 wt% of drug loading PLGA NPs and PLGA-(PLO/fucoidan) 4 NPs were selected for in vitro cumulative drug release study and the cumulative release prole was represented in Fig. 8, Fig. 8a showed 0-72 h drug releasing effect, while Fig. 8b is 0-12 h releasing effect. The drug releasing rate of raw DOX was 80.9% aer 6 h of incubation. PLGA NPs and LbL NPs have shown sustained-release patterns, despite the fact that there was no burst release in either of the nanoparticle formulations. The release of DOX encapsulated in the inner core was more sustained in LbL NPs because of the external multilayered polyelectrolyte shell, which means with the time increasing, DOX released slowly from the inner cores. The drug release was only 3.3% aer 0.5 h, however the drug cumulative release was 57.9% aer 36 h of incubation, and in agreement with the previous report. A few part of DOX remained in polyelectrolyte materials when releasing from the cores, which would not be tested by ultraviolet spectrum. Aer 72 h, the total releasing rate is still under than 60%, compared with the result. 32 Because the remained DOX was still loaded in the inner cores, different polyelectrolyte materials and the number of coats in core-shell design might inuence or decide the drug release ability.
In vitro anti-tumor activity
To evaluate the cytotoxicity of various nanoparticle formulations DOX-PLGA NPs and DOX-PLGA-(PLO/fucoidan) 4 NPs (DOX concentration equivalent to 5 mg mL À1 ) along with the free DOX (5 mg mL À1 ), we observed the cell morphology as well as measured the inhibition rate of NPs treatment in the MCF-7 cells. Images of cell morphology were captured aer incubation with respective treatments for 72 h, as shown in Fig. 9 . It is clear from the images that the DOX loaded NPs (Fig. 9c and d) as well as free DOX (Fig. 9b ) treatment resulted in shrunken morphology, with reduced cell density at the magnied scale compared to the control group, i.e., no treatment group (Fig. 9a) , where cells grew well, with circular or elliptic and large in size. This typical experiment demonstrated that nanoparticles treatment were comparatively more effective than the free DOX treatment group.
Anti-proliferative screening was performed using CCK-8 kit, a sensitive colorimetric assay to epitomize the inhibition results of DOX, DOX-PLGA NPs and DOX-PLGA-(PLO/fucoidan) 4 NPs cocultured with MCF-7 cells (Fig. 10) . The detection sensitivity of this kit is higher than other tetrazolium salts. We have performed both dose as well as time dependent inhibition rate, with increasing doses (1, 5, 10, 25 , and 50 mg mL
À1
) of DOX, DOX-PLGA NPs and DOX-PLGA(PLO/fucoidan) 4 NPs (Fig. 10a) along with time of treatment exposure 24 h. Free DOX, DOX-PLGA NPs, and DOX-PLGA-(PLO/fucoidan) 4 NPs (DOX concentration equivalent to 5 mg mL À1 in NPs) were selected for different time treatments (24, 48 , and 72 h) (Fig. 10b) , respectively. We observed the signicant inhibition with the increasing concentration of NPs and free DOX, the reason behind the cell apoptosis might be the synthesis of RNA and DNA of tumor cells were inhibited by DOX. 26 Similarly, the time of exposure has also inuenced the inhibition rate, i.e., the cell inhibition rate increased with the increase in time of exposure, this might be due to the controlled delivery of DOX from NPs with the elapsing time. In time dependent experiments, 72 h of inhibition effect was lower in free DOX. Since DOX delivered from NPs were more effective with elapsed time than free DOX, due to ease of internalization of nanoparticles might be through endocytosis and sustained release of drug molecules from PLGA-(PLO/fucoidan) 4 nanocarriers. This is mandatory that increasing NPs concentration around tumor could certainly have a chance to kill cells.
Cellular uptake study
It is advantageous that DOX emits red uorescence, where cellular internalization can be traced making use of this benet. We performed cellular uptake study to trace DOX-PLGA NPs and DOX-PLGA-(PLO/fucoidan) 4 NPs co-cultured with MCF-7 cells for 0.5, 2, 4 h using CLSM, as shown in Fig. 11 . The experiment setup possessed two channels, i.e., a DAPI channel for visualizing nucleus (blue in color) and a DOX channel for tracing nanocarriers (red in color), in addition the merged images were also displayed to analyze the close association. This concomitant state that DOX interacted with the cellular components might result in the cell apoptosis. The short time of treatment (i.e., 0.5 h) (Fig. 11a-c) evidenced that the administered NPs were very close proximity, ready to internalize, and the same was achieved by a few of the NPs aer 2 hours (Fig. 11d-f ). In addition, aer 4 hours of treatment, the images represented that the internalized NPs were ample higher and very close proximity to the nucleus, even contemporaneous intra-nuclear (Fig. 11g-i) . These results supports the evidence to the inhibition rate of NPs (Fig. 10) . 
Conclusion
In summary, we prepared PLGA cores using O/W emulsion solvent evaporation method and subsequently, PLGA-(PLO/ fucoidan) n (n ¼ 0.5, 1, 1.5, ., 10) NPs were prepared by the LbL self-assembly technique for the preparation of composite lms of polyelectrolytes (PLO, fucoidan) on the surface of PLGA cores deposited alternatively. Doxorubicin loaded in the PLGA-(PLO/ fucoidan) 4 NPs possessed good sustained drug release ability and ease of cell internalization capability, which have shown an outstanding ability to kill breast tumor cells. These innovative LbL NPs possessing high anti-tumor efficacy could be used as a potential drug delivery vehicle and advantageous over other nanocarriers in medicine.
